Blood-Borne viruses in the haemodialysis, CAPD and renal transplantation setting 2013

Hdl Handle:
http://hdl.handle.net/10147/313617
Title:
Blood-Borne viruses in the haemodialysis, CAPD and renal transplantation setting 2013
Authors:
Health Protection Surveillance Centre (HPSC)
Affiliation:
Health Service Executive (HSE)
Citation:
Health Service Executive, "Blood-Borne viruses in the haemodialysis, CAPD and renal transplantation setting 2013", 2013
Publisher:
Health Service Executive (HSE)
Issue Date:
2013
URI:
http://hdl.handle.net/10147/313617
Item Type:
Report
Language:
en
Description:
End stage kidney disease (ESKD) requires a variety of treatment options including HD, CAPD and transplantation, procedures where infection control is of paramount importance. Chronic HD patients are at high risk of infection because the process of HD requires repeated vascular access for prolonged periods. Such patients are susceptible to person-to-person transmission of infectious agents, directly or indirectly, via contaminated devices, equipment and supplies, environmental surfaces or the hands of personnel. For many years, viral hepatitis was recognised as a hazard for HD patients and staff.1 In 1972, guidelines were issued in the UK for the prevention and control of hepatitis B virus (HBV) in renal and transplant units.2 In the US, recommendations for the control of HBV in HD centres were first published in 1977.3 By 1980, their widespread implementation was associated with a sharp reduction in incidence of HBV infection among both patients and staff members. In 1982, hepatitis B vaccination was recommended for all susceptible patients and staff members.3 Hepatitis C virus (HCV) and human immunodeficiency virus (HIV) were later identified.
Keywords:
KIDNEY DISEASES; INFECTION CONTROL

Full metadata record

DC FieldValue Language
dc.contributor.authorHealth Protection Surveillance Centre (HPSC)en_GB
dc.date.accessioned2014-03-04T12:49:42Z-
dc.date.available2014-03-04T12:49:42Z-
dc.date.issued2013-
dc.identifier.citationHealth Service Executive, "Blood-Borne viruses in the haemodialysis, CAPD and renal transplantation setting 2013", 2013en_GB
dc.identifier.urihttp://hdl.handle.net/10147/313617-
dc.descriptionEnd stage kidney disease (ESKD) requires a variety of treatment options including HD, CAPD and transplantation, procedures where infection control is of paramount importance. Chronic HD patients are at high risk of infection because the process of HD requires repeated vascular access for prolonged periods. Such patients are susceptible to person-to-person transmission of infectious agents, directly or indirectly, via contaminated devices, equipment and supplies, environmental surfaces or the hands of personnel. For many years, viral hepatitis was recognised as a hazard for HD patients and staff.1 In 1972, guidelines were issued in the UK for the prevention and control of hepatitis B virus (HBV) in renal and transplant units.2 In the US, recommendations for the control of HBV in HD centres were first published in 1977.3 By 1980, their widespread implementation was associated with a sharp reduction in incidence of HBV infection among both patients and staff members. In 1982, hepatitis B vaccination was recommended for all susceptible patients and staff members.3 Hepatitis C virus (HCV) and human immunodeficiency virus (HIV) were later identified.en_GB
dc.language.isoenen
dc.publisherHealth Service Executive (HSE)en_GB
dc.subjectKIDNEY DISEASESen_GB
dc.subjectINFECTION CONTROLen_GB
dc.titleBlood-Borne viruses in the haemodialysis, CAPD and renal transplantation setting 2013en_GB
dc.typeReporten
dc.contributor.departmentHealth Service Executive (HSE)en_GB
All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.